Baxalta Inc, founded in 2015 and headquartered in Bannockburn, Illinois, is a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases and complex medical conditions. The company specializes in hematology, immunology, and oncology, offering a range of therapies, including significant advancements in treatments for bleeding disorders and immune deficiencies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| SHPLN 4.00% 2025-06-23 USDBaxalta Inc | United States | 2025-06-23 | 4.000 | 0.00 |
| SHPLN 4.00% 2025-06-23 USDBaxalta Inc | United States | 2025-06-23 | 4.000 | 4.13 |
| SHPLN 4.00% 2025-06-23 USDBaxalta Inc | United States | 2025-06-23 | 4.000 | 0.00 |
| SHPLN 5.25% 2045-06-23 USDBaxalta Inc | United States | 2045-06-23 | 5.250 | 5.58 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Baxalta began issuing bonds shortly after its inception, using proceeds primarily to support corporate operations and expansions. A notable issuance was the $1 billion bond launched in 2016, which featured attractive yields compared to its industry peers at the time. Currently, their bonds are well-regarded due to the company’s solid performance in the biopharmaceutical sector, with yields reflecting a competitive stance within the market. The company's strategic focus on rare diseases continues to bolster investor confidence, positioning its debt instruments favorably amid industry advancements.